MALT1 and glioblastoma: Using two types of glioblastoma patient-derived mesenchymal (GSC#1) and classical (GSC#9) cells with stem-like properties, Jacobs et al. [50] demonstrated that a 24-h treatment of 20 μM fluphenazine is able to reduce 95% of cell viability and attributed this effect to the inhibition of paracaspase mucosa-associated lymphoid tissue l (MALT1) protease, a protein associated with a worse prognosis of the disease.